Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024 - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024

http://www.reportbuyer.com/pharma_healthcare/biotechnology/ortho_osteobiologics_world_industry_market_analysis_2014_2024.html

Report Details

Biotechnology for bone disorders - new study showing you trends, R&D progress, and predicted revenues
What's the future of orthobiologics and osteobiologics? Visiongain's updated report gives you predictions for those medical devices and pharmaceuticals. There you explore sales results, technologies, needs, R&D, opportunities, and revenue forecasts.
So see what's possible for those bone-repairing agents and related biotechnologies for bone diseases. You gain data and financial analysis for that industry. There find technological progress and commercial prospects for technology and medicines. Discover potential gains.
Read on to explore those treatments and see what their future market could be worth.

Forecasts and other analyses of technology for healing damaged bones

Orthobiologics constitute products using biology or biochemistry to treat musculoskeletal disorders. Sales of those drugs and other reconstructive therapies expand.
Our report covers two main segments: bone graft substitutes and biological treatments for osteoporosis. It then analyses components of those submarkets.
That new study gives you sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies in bone repair. There find potentials, hearing how you can gain.
Besides forecasting revenues to 2024, that work shows you historical results, growth rates, and market shares. There you explore technologies, applications, and developments (R&D). You also gain 64 tables, 60 charts, and two interviews with other authorities.

Knowledge to benefit your work and save time, helping your influence

Ever had trouble finding data you need? See in our report how you could help your business research, analyses, and decisions on treatments for debilitating bone conditions. Save time too. Also benefit your authority through better understanding the present and future.
So the following sections explain what you get in our new investigation.
Forecasting of that world market and its main segments - you explore possibilities
What're the secrets of that industry's progress? Where lies potential in treating bone disorders? Discover in our work overall world revenue to 2024 for orthobiologics and biologics for osteoporosis.

Also in that report you find individual revenue predictions to 2024 for six therapeutic submarkets at world level for orthobiologics:

• Machined bone allografts
• Demineralised bone matrices
• Recombinant growth factors
• Bone substitutes
• Stem-cell therapies
• Allograft implants.
There you assess outlooks for sales growth, seeing where you can gain.
So you explore competition and rising sales for products in orthopaedics (orthopedics), and related technology for rebuilding bones, including biological drugs (biologics). You get feel for that sector and its potential.
Discover the lucrative, expanding possibilities there. You also assess top products' futures.
Predictions of leading osteopathic agents' revenues
Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for products, marketed and expected:
• INFUSE
• Prolia
• Forteo
• Preotact
• Romosozumab
• Biosimilars (follow-on biologics) for osteoporosis, grouped analysis.
There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and sales potentials. See where you could profit.
Our work also divides its overall predictions into geographical regions.

Healthcare in leading national markets - what outlooks for those medical sales?

In developed and developing countries, opportunities for providers of bone treatments will increase from 2014 to 2024. See where and how, finding sales potentials for therapeutics.
Separately for orthobiologics and biologics for osteoporosis, our analyses show you individual revenue forecasts to 2024 for 11 national markets:
United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.
There you find countries with highest revenues, demand, and potential revenue growth. Our work explains. You assess needs and demands for that specialist medicine.
Explore, too, how that biomedical and biopharma technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing trends and needs.

Events and forces for developing, producing, marketing, and selling those bone medicines

Our report shows you issues and events affecting that biomedical and pharmaceutical sector from 2014, including these:
• Bisphosphonates to monoclonal antibodies (mAbs) - therapies to improve bone density
• Bone graft substitutes, orthopaedic devices and biologics suiting minimally-invasive surgery, inc. orthopaedic biomaterials
• Stem cell therapies and Map3 and i-Factor bone grafts
• Expanding markets for bone therapy, including effect of demographics on demand
• Research and development (R&D) pipelines, inc. donor cell therapy, tibia fusing, spinal fusion, mimetic peptides, romosozumab, and blosozumab.
So you explore political, economic, social, and technological questions for treating bone disorders, investigating outlooks for commerce. Discover what the future holds.
Examine, then, what stimulates and restrains players in that industry, and affects its results.

Companies and 2018 market value - find prospects for success

What happens next? From 2014 novel treatments and regulations there encourage investments, medical advances, and higher revenues.
So our study predicts the world market for orthobiologics will reach $4,561m in 2018. There big pharma and specialty companies can gain, expanding business. Explore how and where.
And there you examine activities of many organisations, including these participants:
• Eli Lilly
• Amgen
• Medtronic
• Johnson & Johnson (DePuy Synthes)
• NuVasive.
Also these firms, among others:
• Baxter International
• Biomet
• Zimmer
• RTI Biologics.
R&D for treating bone damage holds advantages, and from 2014 there will arise many opportunities. From this decade, patients, payers, and producing companies will benefit.
And you discover how those market segments can perform, staying ahead in knowledge.

Ways Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024 helps

In particular, that new investigation gives you these advantages:
• Revenues there to 2024 at world level, for 7 submarkets, and 5 products - examine outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - assess developed and developing countries for potential revenues
• Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, successes, and developmental activities.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the business possibilities.
With our data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort with our study, helping your planning, decisions, and authority.

1. Executive Summary

1.1 Overview of Findings
1.2 Aims and Coverage of this Report
1.3 Structure of this Report
1.4 Research and Analysis Methods
1.5 Terms Related to This Report

2. Introduction to Orthobiologics

2.1 What Are Orthobiologics?
2.2 How Do we Classify Orthobiologics?
2.3 Osteoblasts are Critical in Bone Healing
2.4 Autografts - The "Gold Standard" Bone Graft
2.5 Allografts- The Most Basic of Orthobiologics
2.6 Machined Bones- Creating Customised Implants
2.7 Demineralised Bone Matrix (DBM) - The Original Osteoinductive Orthobiologic
2.8 Growth Factors, the Signals That Encourage Tissue Formation
2.8.1 Bone Morphogenetic Proteins (BMPs) - Supercharging Osteoinduction
2.9 Stem Cells - The Future of Orthobiology
2.10 Regulation of Orthobiologics
2.10.1 The US Approval and Regulation System
2.10.2 The EU Approval and Regulation System
2.11 Osteoporosis - The Insidious Killer
2.12 From Bisphosphonates to Antibodies - Therapies to Improve Bone Density
2.13 Biological Treatments for Osteoporosis - Monoclonal Antibodies Just Hitting the Market

3. Orthobiologics: Global Market, 2014-2024

3.1 Orthopaedic Devices: Worth More Than $29bn in 2012
3.2 Orthobiologics in 2012, a Diverse Multi-Billion Dollar Market
3.2.1 Trends in Orthobiologics, 2012
3.3 Which Segments Will Grow Fastest? Orthobiologics Market Forecast Breakdown, 2014-2024
3.3.1 Steady Growth in Machined Bones, 2014-2024
3.3.2 Growth Spurt in Demineralised Bone Matrices, 2014-2024
3.3.3 Declining Growth Factor Sales, 2014-2024
3.3.4 Accelerated Growth for Bone Substitutes, 2013-2024
3.3.5 Sustained High Growth for Stem-Cells Therapies, 2014-2024
3.3.6 Allograft Market Remains Small, 2014-2024
3.4 Stem-Cell Therapies will lead the Orthobiologics Market
3.4.1 Stem-Cell Therapies: Drivers and Restraints
3.4.2 The Only Osteogenic Bone Graft Substitute
3.4.3 Better than Autograft
3.4.4 Treating at Risk Patients
3.4.5 What is the Alternative?
3.4.6 High Costs Limit Access
3.4.7 Where is the Clinical Evidence?
3.4.8 Human Tissue or Biological Product?
3.5 Growth Factors Fall From Grace
3.5.1 Growth Factor Products: Drivers and Restraints
3.5.2 Autograft Equivalence
3.5.3 Surgeons Still like INFUSE
3.5.4 Off-label Adverse Events
3.5.5 High Unit Cost
3.5.6 Stem-Cell Competition

4. Regional and National Markets, 2014-2024

4.1 US and Japan are Crucial National Markets - Regional Breakdown of the Orthobiologics Market, 2012
4.2 Japan and Germany Increase Market Share by 9%: National Markets, 2012-2018
4.3 BRIC Countries Increase Market Share by 38%: National Markets, 2018-2024
4.4 National Orthobiologic Market Analysis, 2014-2024
4.5 The US Remains Fundamental to Growth: Market Forecast, 2014-2024
4.5.1 Demographics, Drivers and Restraints
4.6 Steady Growth for Orthobiologics in the Five Leading European Nations, 2014-2024
4.6.1 Demographics, Drivers, and Restraints
4.7 Germany Leads Europe: Market Forecast, 2014-2024
4.7.1 Demographics, Drivers, and Restraints
4.8 Expanding Orthobiologics in the UK: Market Forecast, 2014-2024
4.8.1 Demographics, Drivers, and Restraints
4.9 Slow Growth in the French Orthobiologics: Market Forecast, 2014-2024
4.9.1 Demographics, Drivers, and Restraints
4.10 Stuttering Growth for Orthobiologics in Italy: Market Forecast, 2014-2024
4.11 Dwindling Demand in Spain: Market Forecast, 2014-2024
4.12 The Rise of Orthobiologics in Japan: Market Forecast, 2014-2024
4.12.1 Demographics, Drivers, and Restraints
4.13 BRIC Nations to Increase Market Share by 42%: Regional Market Forecast, 2014-2024
4.14 China, the Principal Emerging Nation: Market Forecast, 2014-2024
4.14.1 Demographics, Drivers, and Restraints
4.15 Explosive Growth in Brazilian Orthobiologics: Market Forecast, 2014-2024
4.15.1 Demographics, Drivers, and Restraints
4.16 Too Soon for Orthobiologics in India: Market Forecast, 2014-2024?
4.17 Tepid Growth in Russian Orthobiologics: Market Forecast, 2014-2024
4.17.1 Demographics, Drivers, and Restraints
4.18 Orthobiologics in Minor Nations: Market Forecast, 2014-2024

5. Biological Treatments for Osteoporosis: Market to 2024

5.1 Biologics Take 21.9% of the Osteoporosis Market in 2012
5.2 Leading Biologic Brands
5.2.1 Prolia (Denosumab; Amgen)
5.2.2 Forteo (Teriparatide; Eli Lilly)
5.2.3 Preotact (Recombinant Parathyroid Hormone; NPS Pharmaceuticals)
5.3 Forteo Spearheads the Market in 2012
5.4 Rapid Growth for Biologics: Global Market Forecast, 2014-2024
5.5 Forecasted Product Sales, 2014-2024
5.5.1 Prolia to Drive the Market
5.5.2 Forteo Loses Market Share
5.6 National Breakdown of the Osteobiologics Market, 2012
5.7 Declining Importance of Europe: Forecasted National Markets 2014-2024
5.8 US Dictates Growth: Market Forecast, 2014-2024
5.8.1 Demographics, Drivers, and Restraints
5.9 European Market Share to Decline by 27% Over Ten Years
5.10 German Market to Plateau: Market Forecast 2014-2024
5.10.1 Demographics, Drivers, and Restraints
5.11 Revenue Ceiling in the UK: Market Forecast 2014-2024
5.11.1 Demographics, Drivers, and Restraints
5.12 French Market to Double in Five Years: Market Forecast 2014-2024
5.12.1 Demographics, Drivers, and Restraints
5.13 Price Controls Restrict Italian Growth: Market Forecast 2014-2024
5.13.1 Demographics, Drivers, and Restraints
5.14 Limited Expansion in Spain: Market Forecast 2014-2024
5.14.1 Demographics, Drivers, and Restraints
5.15 Continual Growth in Japan: Market Forecast 2014-2024
5.15.1 Demographics, Drivers, and Restraints
5.16 BRIC Nations to Treble in Value in Less Than Ten Years
5.17 China Increases Market Share by 48%: Market Forecast 2014-2024
5.17.1 Demographics, Drivers, and Restraints
5.18 Brazil Set to Expand by 185%: Market Forecast, 2014-2024
5.18.1 Demographics, Drivers, and Restraints
5.19 Strong Growth but Poor Value in India: Market Forecast 2014-2024
5.19.1 Demographics, Drivers, and Restraints
5.20 Limited Value in Russia: Market Forecast 2014-2024
5.20.1 Demographics, Drivers, and Restraints
5.21 Minor National Markets Forecast, 2014-2024

6. R&D Pipeline for Orthobiologics

6.1 Orthobiologic Biomaterials Pipeline
6.1.1 i-FACTOR (Cerapedics) - Osteoinduction Without Hazardous Growth Factors
6.1.2 Bone Therapeutics, Focussed on Cell Therapies
6.1.2.1 PREOB - Leading Candidate For Non-Union and Osteoporosis
6.1.2.2 ALLOB - Early Stage Donor Cell Therapy
6.1.3 Map3 (RTI Biologics) - Competition for Osteocel and Trinity Evolution
6.1.4 NeoFuse (Mesoblast) - Comparable to the "Gold Standard"
6.1.5 Kuros Biosurgery - Partnered With Synthes to Develop Orthobiologics
6.1.5.1 KUR-111 - An Alternative to Autograft for Fusing the Tibia
6.1.5.2 KUR-113 - Another Parathyroid Hormone for Tibia Fractures
6.1.5.3 KUR-115 - About to Enter Phase II Trials for Spinal Fusion
6.1.6 Amplex (BioSET) - A Mimetic Peptide for BMP-2
6.1.7 UCB-1 (Nell-1; Bone Biologics) - Early Stage Protein with Sclerostin like Potential
6.2 Biological Osteoporosis Pipeline
6.2.1 Romosozumab (AMG 785) - Blockbuster in Waiting
6.2.2 Blosozumab (LY2541546) - Second in Class Sclerostin Antibody
6.2.3 ZP-PTH - Parathyroid by Way Micro Needle Patch
6.2.4 ZT-034 - Will Need More Than Biomarkers for Approval
6.2.5 BA058 - Looking to Compete With Forteo

7. Leading Companies in the Orthobiologics Market, 2013-2014

7.1 Domination of Medtronic and Johnson & Johnson
7.2 Leading Companies in the Orthobiologics Market, 2013
7.3 Medtronic
7.3.1 INFUSE Sales Results
7.4 Johnson & Johnson (DePuy Synthes), Dominant in the Orthobiologics and Medical Device Market
7.5 Vitoss Crucial to Stryker Sales
7.6 Integra LifeSciences, Looking to Innovation with Accell DBMs
7.7 NuVasive - The Leading Force in the Stem Cell Market
7.8 RTI Biologics, Producing the Full Spectrum of Orthobiologics
7.9 Baxter International, Acquiring Its Way into the Market
7.10 Biomet - Big in Orthopaedics, Building Up in Orthobiologics
7.11 Wright Medical, Shifting Focus into the Ankle Market
7.12 Globus Medical- The Fastest Growing Orthopaedics Company
7.13 Zimmer Spine, Weak Sales for a Multinational Powerhouse
7.14 Bacterin - Exclusively Biological Business Model
7.15 Olympus Biotech, Focussed on Minimally Invasive Surgery
7.16 Fragmented Market for Smaller Companies
7.17 Shift to High Margin Products and Specialisation

8. Qualitative Analysis of the Orthobiologics Market, 2014

8.1 Strengths and Weaknesses of the Orthobiologics Market
8.2 Strengths
8.2.1 Eli Lilly and Amgen Dominate the Biological Osteoporosis Market
8.2.2 Biologics Suit Minimally Invasive Surgery
8.2.3 Patients Stick to Biologics
8.3 Weaknesses
8.3.1 Intense Competition in the Biomaterials Market
8.3.2 Are Biologics Worth the Bill?
8.3.3 Soaring Clinical Development Costs
8.3.4 The Silent Disease
8.4 Opportunities and Threats in the Orthobiologics Market
8.5 Opportunities
8.5.1 Increase Diagnosis Rates to Increase Sales
8.5.2 Beat the Best in Class
8.5.3 Access to the Surgical Community
8.5.4 Replacing Autografts
8.6 Threats
8.6.1 Generic Bisphosphonate Competition
8.6.2 Getting Paid in the US and Europe
8.6.3 Accessing the Asian Markets
8.6.4 Treatment Only as a Last Resort
8.7 Social, Technological, Economic, and Political (STEP) Analysis
8.7.1 Social Factors
8.7.2 Ageing Populations in the Developed and BRIC Nations
8.7.3 Unhealthy Lifestyles and the Global rise in Prevalence of Diabetes
8.8 Technological Factors
8.8.1 Harnessing Stem Cell and Gene Based Therapies
8.9 Economic Factors
8.9.1 Reimbursement and Cost Cutting in the Europe and the US
8.9.2 Free Trade within the European Union, Parallel Trade and Arbitrage
8.9.3 Record Low Cost of Borrowing - What Happens When the Music's Over?
8.10 Political Factors
8.10.1 The Patient Protection and Affordable Care Act in the US

9. Research Interviews

9.1 Interview with an Executive at an International Orthobiologics Company
9.1.1 Matching Products to Patients at Risk
9.1.2 Demanding Clinical and Economic Evidence
9.1.3 Stem Cells are Critical
9.1.4 Developed Markets and Latin America Drive Growth
9.1.5 Too Early for China?
9.1.6 Moving Away From Basic Bone Substitutes
9.1.7 Medical Education is Crucial
9.1.8 Safety and Efficacy of BMP Products
9.2 Interview with Dr Nancy Epstein M.D., Chief of Neurosurgical and Spine Education, Winthrop University Hospital
9.2.1 INFUSE to be taken off the Market
9.2.2 An "Off-label" Product NOT Approved by the Food and Drug Administration
9.2.3 Surgeons Still Demand Innovation for Patients at Risk
9.2.4 Gene Therapy

10. Conclusions

10.1 Continued Growth in Orthobiologics
10.1.1 Stem-Cell Products Dominate the Market
10.1.2 Decline in Growth Factor Sales
10.1.3 US Continues to Dominate the Market
10.2 Biologics Break Osteoporosis
10.2.1 Patient Population Explosion
10.2.2 Prolia and Romosozumab Lead the Market
10.2.3 Early Access to Japan

List of Tables

Table 2.1 Mechanisms Involved in Bone Grafting
Table 3.1 Global Orthopaedic Device Market: Segment Revenue ($bn) and Market Share (%), 2012
Table 3.2 Global Orthobiologics Market: Segment Revenue ($m) and Market Share (%), 2012
Table 3.3 Global Orthobiologics Market Forecasts: Segment Revenue ($m), Annual Growth Rate (%), Segment Market Share (%), CAGR (%), 2012-2018
Table 3.4 Global Orthobiologics Market Forecasts: Segment Revenue ($m), Annual Growth Rate (%), Segment Market Share (%), CAGR (%), 2018-2024
Table 3.5 Global Machined Bone Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.6 Global Demineralised Bone Matrix Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.7 Global Growth Factor Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.8 Global Bone Substitute Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.9 Global Stem Cell Therapy Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.10 Global Allograft Bone Market Forecast: Revenue ($m) Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.11 INFUSE Revenue Forecast: Revenue ($m), Annual Growth Rate (%), Peak of Sales (%), CAGR (%), 2011-2024
Table 4.1 Global Orthobiologics Market: National Market Revenue ($m), Market Share (%), 2012
Table 4.2 Global Orthobiologic Market: National Market Revenue ($m), Market Share (%), 2018
Table 4.3 Global Orthobiologic Market: National Market Revenue ($m), Market Share (%), 2024
Table 4.4 Global Orthobiologics Market: Regional Revenue Forecasts ($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2013-2018
Table 4.5 Global Orthobiologics Market: Regional Revenue Forecasts($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2018-2024
Table 4.6 US Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.7 Five Leading European Orthobiologic Markets: National Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), CAGR (%), 2013-2018
Table 4.8 Five Leading European Orthobiologic Markets: National Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), CAGR (%), 2018-2024
Table 4.9 German Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.10 UK Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.11 French Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.12 Italian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.13 Spanish Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.14 Japanese Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.15 BRIC Orthobiologic Markets: Revenue Forecasts ($m), Annual Growth (%), BRIC Market Share (%), CAGR (%), 2013-2018
Table 4.16 BRIC Orthobiologic Markets: Revenue Forecasts ($m), Annual Growth (%), BRIC Market Share (%), CAGR (%), 2018-2024
Table 4.17 Chinese Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.18 Brazilian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.19 Indian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.20 Russian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 4.21 Minor National Orthobiologic Markets: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.1 Global Osteoporosis Market: Segment Revenue ($m), Market Share (%), 2012
Table 5.2 Biologics Osteoporosis Treatments, Product Revenue ($m) and Market Share (%), 2012 and 2013
Table 5.3 Global Osteoporosis Biologics Market Forecast: Total Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 5.4 Global Osteoporosis Biologics Market Forecasts: Product Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2018
Table 5.5 Global Osteoporosis Biologics Market Forecasts: Product Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2018-2024
Table 5.6 National Markets for Osteoporosis Biologics: Revenue ($m), Market Share (%), 2012
Table 5.7 Global Osteoporosis Biologics Market: Regional Revenue Forecasts ($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2013-2018
Table 5.8 Global Osteoporosis Biologics Market: Regional Revenue Forecasts ($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2018-2024
Table 5.9 US Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.10 Reported Costs of Biological Osteoporosis Treatments in the US and UK Markets, 2013
Table 5.11 Five Leading European Nationals Markets for Osteoporosis Biologics: Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), Global Market Share (%), CAGR (%), 2013-2018
Table 5.12 Five Leading European Nationals Markets for Osteoporosis Biologics: Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), Global Market Share (%), CAGR (%), 2018-2024
Table 5.13 German Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.14 UK Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.15 French Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.16 Italian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.17 Spanish Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.18 Japanese Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.19 BRIC Markets for Osteoporosis Biologics: National Revenue Forecasts ($m), Annual Growth Rate (%), BRIC Market Share (%), Global Market Share (%), CAGR (%), 2013-2018
Table 5.20 BRIC Markets for Osteoporosis Biologics: National Revenue Forecasts ($m), Annual Growth Rate (%), BRIC Market Share (%), Global Market Share (%), CAGR (%), 2018-2024
Table 5.21 Chinese Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.22 Brazilian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.23 Indian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.24 Russian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 5.25 Minor National Markets for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
Table 6.1 Orthobiologic Biomaterials in Development, 2013
Table 6.2 Osteoporosis Biologics in Development, 2013
Table 7.1 Leading Orthobiologics Companies: Revenue ($m), Market Share (%), 2012
Table 7.2 INFUSE (rhBMP-2) Sales: Revenue ($m), Annual Growth Rate (%), Peak of Sales (%), CAGR, 2010-2014
Table 7.3 Smaller Orthobiologics Manufacturers: Listed A-E, 2013
Table 7.4 Smaller Orthobiologics Manufacturers: Listed G-T, 2013

List of Figures

Figure 3.1 Orthopaedic Devices Market: Segment Market Shares (%), 2012
Figure 3.2 Global Orthopaedics Biomaterials Market: Segment Market Shares (%), 2012
Figure 3.3 Segmented Orthobiologics Market Forecast: Segment Revenues ($m), 2013-2024
Figure 3.4 Total Global Orthobiologics Forecast: Revenue ($m), 2013-2024
Figure 3.5 Machined Bone Market Forecast: Revenue ($m), 2013-2024
Figure 3.6 Global Demineralised Bone Matrix Market Forecast: Revenue ($m), 2013-2024
Figure 3.7 Global Growth Factor Market Forecast: Revenue ($m),2013-2024
Figure 3.8 Global Bone Substitute Market Forecast: Revenue ($m), 2013-2024
Figure 3.9 Global Stem Cell Therapy Market Forecast: Revenue ($m), 2013-2024
Figure 3.10 Global Allograft Bone Market Forecast: Revenue ($m), 2013-2024
Figure 3.11 Stem-Cell Therapy Market: Drivers and Restraints, 2014-2024
Figure 3.12 INFUSE Revenue Forecast: Revenue ($m), 2013-2024
Figure 3.13 Growth Factor Market: Drivers and Restraints, 2014-2024
Figure 4.1 Global Orthobiologics Market: National Market Shares (%), 2012
Figure 4.2 Global Orthobiologic Market: National Market Shares (%), 2018
Figure 4.3 Global Orthobiologic Market: National Market Shares (%), 2024
Figure 4.4 Global Orthobiologics Market: Regional Revenues ($m), 2013-2024
Figure 4.5 US Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.6 Five Leading European Orthobiologic Markets: National Market Revenues ($m), 2013-2024
Figure 4.7 German Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.8 UK Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.9 French Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.10 Italian Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.11 Spanish Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.12 Japanese Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.13 BRIC Orthobiologic Markets: National Revenues ($m), 2013-2024
Figure 4.14 Chinese Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.15 Brazilian Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.16 Indian Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.17 Russian Orthobiologic Market: Revenue ($m), 2013-2024
Figure 4.18 Minor National Orthobiologic Market: Revenue ($m), 2013-2024
Figure 5.1 Global Osteoporosis Market, Segment Market Shares (%), 2012
Figure 5.2 Biologics Osteoporosis Treatments: Product Revenue ($m), 2012 and 2013
Figure 5.3 Global Osteoporosis Biologics Market Forecast: Total Revenue ($m), 2013-2024
Figure 5.4 Global Osteoporosis Biologics Market Forecast: Product Revenues ($m), 2013-2024
Figure 5.5 Global Prolia Market Forecast: Revenue ($m), 2013-2024
Figure 5.6 Global Forteo Market Forecast: Revenue ($m), 2013-2024
Figure 5.7 Global Preotact Market Forecast: Revenue ($m), 2013-2024
Figure 5.8 Global Romosozumab Market Forecast: Revenue ($m), 2013-2024
Figure 5.9 Global Generics Market: Revenue ($m), 2013-2024
Figure 5.10 National Markets for Osteoporosis Biologics: Market Shares (%), 2012
Figure 5.11 Global Osteoporosis Biologics Market: Regional Revenues ($m), 2013-2024
Figure 5.12 US Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.13 Five Leading European National Markets for Osteoporosis Biologics: Revenues ($m), 2013-2024
Figure 5.14 German Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.15 UK Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.16 French Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.17 Italian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.18 Spanish Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.19 Japanese Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.20 BRIC Markets for Osteoporosis Biologics: Revenues ($m), 2013-2024
Figure 5.21 Chinese Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.22 Brazilian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.23 Indian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.24 Russian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 5.25 Minor National Markets for Osteoporosis Biologics: Revenue ($m), 2013-2024
Figure 7.1 Leading Orthobiologics Companies: Revenues ($m), 2012
Figure 7.2 INFUSE (rhBMP-2) Sales: Revenue ($m), 2010-2014
Figure 8.1 Orthobiologics Market: Strengths and Weaknesses, 2014-2024
Figure 8.2 Orthobiologics Market: Opportunities and Threats, 2014-2024

Companies Listed

AAP Implante
Allosource
Alphatec
Amgen
Angel Biotechnology
ApaTech
Arthrocare
Atheriocyte Medical Systems Inc
Athersys
Azelon Pharmaceuticals
Bacterin
Baxter
Berkeley Advanced Biomaterials Inc
Biocomposites
Biocoral
Biological Therapies
Biomatlante
Biomet
BioMimetic Therapeutics
BioSET
BioTissue
BonAlive Biomaterials
Bone Biologics
Bone Solutions
Bone Therapeutics
BoneSupport
Brazilian Unified Health System (SUS)
Cardium Therapeutics
Celltech
Centre for Devices and Radiological Health (CDRH)
Ceramisys
Cerapedics
co.don
Collagen Matrix
Curasan
Cytomedix
Daiichi Sankyo
DePuy Synthes
Eli Lilly
ETEX Corporation
European Medicines Agency (EMA)
European Union (EU)
Exactech
Fitch Ratings
Food and Drug Administration (FDA)
Forest Laboratories
Geistlich Biomaterials
German Institute for Quality and Efficiency in Healthcare (IQWiG)
GlaxoSmithKline (GSK)
Globus Medical
Graftys
Histogenics Corporation
Integra LifeSciences
ISTO Technologies
Johnson & Johnson
Kasios
Kensey Nash
Kinetic Concepts
Kuros Biosurgery
Lindare Medical
Medtronic
Merck & Co
Mesoblast
MicroPort Medical
MiMedx Group
Monet Medical
Musculoskeletal Transplant Foundation
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
NovaBone Products LLC
Novartis
NPS Pharmaceuticals
NuVasive
Nycomed
Olympus Biotech
Orteq Bioengineering
Orthofix
Orthovita
Osiris Therapeutics
OsteoGeneX
Osteotech
Parcell Laboratories
Pharma and Medical Devices Agency (PMDA)
Pioneer Surgical Technologies
PolyNovo Biomaterials
Progenteq
Radius Health
Roche
Royal DSM
RTI Biologics
Scorpion Medical
Spinal Restoration
SpineSmith Partners LP
State Food and Drug Administration (SFDA, China)
Stryker
Takeda
Teknimed
Teva Pharmaceutical Industries
Tigenix
Tissue Banks International
Tissue Genesis
TissueGene
Tornier
UCB
Winthrop University Hospital
World Health Organization (WHO)
Wright Medical
Yale University
Zimmer
Zosano Pharma

Read the full report:
Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024

http://www.reportbuyer.com/pharma_healthcare/biotechnology/ortho_osteobiologics_world_industry_market_analysis_2014_2024.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.